iStent with cataract surgery lowers IOP at 8 years in pseudoexfoliation glaucoma
Click Here to Manage Email Alerts
WASHINGTON — Patients with pseudoexfoliation glaucoma treated with iStent plus cataract surgery had sustained IOP reduction at 8 years postop, according to a study.
Tanner J. Ferguson, MD, presented results of the retrospective case review at the American Society of Cataract and Refractive Surgery meeting.
“We’ve previously published this study with results up to 2 years and 5 years,” he said. “This current study represents a continuation out to 8 years postoperatively.”
The study comprised 117 consecutive eyes from patients who underwent implantation of one iStent (Glaukos) with concomitant cataract surgery, with data collected at baseline and at 1 day, 1 week and 1 month out to 8 years after surgery. The primary outcome measures included IOP and number of glaucoma medications.
At baseline, the mean IOP was 20.5 mm Hg. At 8 years, patients experienced sustained IOP reduction, with a mean IOP of 15.4 mm Hg (P < .001).
The baseline mean number of medications was 1.4. At year 8, the mean number of medications was 1.2.
In a proportional analysis, at year 8, 96% of eyes had an IOP of 18 mm Hg or less while 39% had an IOP of 15 mm Hg or less compared with 21% and 11%, respectively, at baseline.
Ferguson said the safety profile was favorable, with only eight eyes needing additional surgeries, all of which were secondary MIGS procedures.
“This represents the longest follow-up data evaluating the first iStent in pseudoexfoliative glaucoma,” Ferguson said. “At 8 years in the consistent cohort, we see about a 5 mm Hg or 25% reduction in IOP.”
Collapse
Ferguson T. Trabecular microbypass stent implantation with cataract extraction in pseudoexfoliative glaucoma: Long-term results. Presented at: American Society of Cataract and Refractive Surgery meeting; April 22-26, 2022; Washington.
Read more about
Click Here to Manage Email Alerts